1FME Stock Chart & Stats
€38.87
-€0.53(-1.19%)
At close: 4:00 PM EST
€38.87
-€0.53(-1.19%)
Day’s Range― - ―
52-Week Range€19.00 - €64.00
Previous CloseN/A
Volume0.00
Average Volume (3M)24.00
Market Cap
€11.81B
Enterprise Value€21.37K
Total Cash (Recent Filing)€1.24B
Total Debt (Recent Filing)€11.03B
Price to Earnings (P/E)13.6
Beta0.45
Next Earnings
Aug 04, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.28
Shares Outstanding268,564,640
10 Day Avg. Volume27
30 Day Avg. Volume24
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.82Price Target Upside-0.12% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering12
EPS Forecast (FY)3.99
Revenue Forecast (FY)€19.36B
Bulls Say, Bears Say
Bulls Say
Cash GenerationMaterial free cash flow (~€1.79B) and ~65% cash conversion provide durable financial flexibility. Strong FCF supports reinvestment in clinics and products, dividend funding and debt reduction, enabling multi-month resilience to operating volatility and strategic optionality.
Improving LeverageLeverage has meaningfully declined from prior highs, lowering refinancing and liquidity risk. An improving debt/equity profile enhances capacity for capex, bolt-on M&A or dividend support and reduces interest burden, strengthening the firm’s structural balance sheet over coming months.
Integrated Care + Products ModelA dual model (clinics plus dialysis products) creates recurring consumable demand from an installed base and opens cross-sell paths. Vertical integration and scale of services and disposables underpin long-term revenue stickiness and competitive barriers versus single-segment peers.
Bears Say
Stagnant Top LineA largely flat revenue trend constrains operating leverage and long-term organic growth prospects. Without sustained patient volume growth, reimbursement improvements, or meaningful expansion, revenue stagnation will limit margin expansion and returns over the next several months.
Modest MarginsRelatively low net and EBIT margins reduce the buffer against cost inflation and pricing pressure in healthcare. Modest profitability limits free cash flow upside and requires continued operational improvements to lift returns, making outcomes sensitive to reimbursement and cost trends.
Reimbursement And Regulatory ExposureHeavy dependence on government and insurer payment rules creates structural policy risk: reimbursement cuts or regulatory shifts in major markets can materially affect volumes, pricing and margins. This exposure can persist for months and materially alter cash flow trajectories.
1FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was €19.00 and its highest was €64.00 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is €11.81B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Aug 04, 2026 which is tomorrow.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on May 05, 2026. The company reported €0.91 earnings per share for the quarter, missing the consensus estimate of €1.012 by -€0.102.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA does not currently pay dividends.
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.07.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of €0.91 in its last earnings report, missing expectations of €1.012. Following the earnings report the stock price went down -11.558%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in IT:1FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€38.82 (-0.12% Downside)
€38.82 (-0.12% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.62%
12-Months-Change
Fundamentals
Return on Equity
3.35%
Trailing 12-Months
Asset Growth
-3.87%
Trailing 12-Months
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
1FME Stock 12 Month Forecast
Average Price Target
€38.82
▼(-0.12% Downside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―








